Ultra-low cholesterol targets for very high-risk heart disease
Part of Heart & circulation clinical trials.
This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years
- History of multiple heart attacks, strokes, or severe blockages (at least 2 major events in the past 2 years, or 1 event plus diabetes, family history of early heart disease, or high lipoprotein(a))
- LDL cholesterol still ≥1.0 mmol/L even after taking maximum-dose statin and ezetimibe for at least 4 weeks
- Able to attend follow-up visits and complete blood tests
- No severe liver or kidney disease, recent major bleeding, or active cancer expected to shorten life significantly
- Not pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how to lower “bad” cholesterol (LDL) in people age 75 and older who have already had heart, brain, or leg/blood-vessel problems from blocked arteries. The goal is to see if the approach helps prevent further cardiovascular events (like heart attack or stroke).
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This Phase 3 study tests whether JS002 alone can lower LDL “bad” cholesterol in people whose levels are still too high for their heart-risk level. It will also check how safe the treatment is, especially for heart and metabolic side effects.
This trial tests a new investigational medicine (SYH2053) for people with high cholesterol or mixed hyperlipidemia who are already on cholesterol-lowering therapy but still have high levels of 'bad cholesterol' (LDL-C). The goal is to see if this add-on treatment can help lower cholesterol further and reduce heart disease risk.
This study tests whether an educational program can help people with high cholesterol and heart disease get their LDL cholesterol levels lower. It involves watching online videos and working with your doctor to adjust treatments.
This study is testing whether reaching a very low LDL cholesterol level (below 1.0 mmol/L) is better than a slightly higher target (1.0-1.8 mmol/L) for people at very high risk after receiving a heart stent. It aims to reduce future heart problems.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.